Skip to Main Content
  • Become an Access Reviewer
  • Clinical Phenotypes
  • OMMBID Advisory banner
  • Ommbid banner
  • Ommbid latest banner


Abstract  †Deceased July 21, 1998.


  1. Lecithin cholesterol acyltransferase (LCAT) is a plasma enzyme that esterifies free cholesterol present in circulating plasma lipoproteins.

  2. LCAT deficiency leads to the development of two clinically distinct syndromes: familial LCAT deficiency (FLD) and fish eye disease (FED).

  3. FLD is characterized by corneal opacities, anemia, and proteinuria that may progress to renal failure. Foam cells and membrane-bound vesicles, which appear to be composed of cholesterol and phospholipid, accumulate in many tissues including the cornea, kidneys, liver, spleen, bone marrow, and arteries. Target cells containing abnormally high amounts of unesterified cholesterol and lecithin are present. Plasma contains high levels of unesterified cholesterol and phospholipids and low concentrations of plasma cholesteryl esters and lysophosphatidylcholine. Plasma triglycerides are normal to increased, low density lipoprotein (LDL) levels are reduced, and high-density lipoprotein (HDL) levels are markedly decreased. The morphology of the lipoproteins is abnormal, with the presence in plasma of multilamellar vesicles, rouleaux, LpX-like particles, discs, and small spherical particles. The diagnosis of FLD is confirmed by a virtual absence of plasma LCAT activity in patients presenting with hypoalphalipoproteinemia, anemia, proteinuria, or renal disease.

  4. FED is characterized by corneal opacities. The plasma triglyceride levels are normal to increased, and HDL levels are markedly decreased. The diagnosis of FED is confirmed by finding a partial deficiency of LCAT activity in the plasma of patients presenting with corneal opacities and marked hypoalphalipoproteinemia.

  5. The LCAT gene is organized into six exons interrupted by five introns and is located on the long arm of chromosome 16. Approximately 40 different mutations in the LCAT gene leading to either FLD or FED have been described to date.

  6. Characterization of FLD and FED patients as well as different LCAT-transgenic and knockout animal models has demonstrated an important role for LCAT in modulating the metabolism of both HDLs and LDLs, as well as the development of atherosclerosis.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.

$295 USD
Buy Now

Pay Per View: Timed Access to all of OMMBID

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.